From Roadmap to Reality: Validating NAMs for FDA's Plan to Phase Out Animal Testing
By Yiguang Zhu | May 15th, 2025
“The FDA and the broader scientific community recognize NAMs as a means to obtain 'faster and more accurate human risk assessments' while reducing animal use.”
Image by ChatGPT
The Utility of an Intra-Agency NAM Office
By Breanne Kincaid | January 10th, 2025
“…the FDA’s NAM office represents a strategic evolution in integrating innovative methodologies into regulatory science. While it complements ICCVAM’s mission, its intra-agency focus and regulatory authority position it to drive faster, more context-specific advancements in risk assessment.“